TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?

Gut. 2019 Aug;68(8):1531-1533. doi: 10.1136/gutjnl-2018-316845. Epub 2018 Jul 14.

Authors

Bram Verstockt^{1

2}, Sare Verstockt³, Helene Blevi², Isabelle Cleynen³, Magali de Bruyn², Gert Van Assche^{1

2}, Séverine Vermeire^{1

2}, Marc Ferrante^{1

2}

Affiliations

¹ Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
² Department of Chronic Diseases, Metabolism and Ageing, Translational Research Centre for Gastrointestinal Disorders (TARGID-IBD), KU Leuven, Leuven, Belgium.
³ Laboratory for Complex Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.

PMID: 30007919
DOI: 10.1136/gutjnl-2018-316845

No abstract available

Keywords: crohn’s disease; ibd clinical; infliximab; tnf-alpha.

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Adalimumab
Biomarkers
Biopsy
Crohn Disease*
Humans
Infliximab
Triggering Receptor Expressed on Myeloid Cells-1
Tumor Necrosis Factor-alpha

Substances

Biomarkers
Triggering Receptor Expressed on Myeloid Cells-1
Tumor Necrosis Factor-alpha
Infliximab
Adalimumab